Understanding Diabetic Ketoacidosis

Diabetic ketoacidosis (DKA) is an acute, life‑threatening metabolic emergency that primarily occurs in patients with type 1 diabetes, though it can also affect those with type 2 diabetes under extreme stress. The underlying mechanism involves an absolute or relative deficiency of insulin coupled with an increase in counter‑regulatory hormones such as glucagon, cortisol, and catecholamines. This hormonal imbalance triggers uncontrolled lipolysis, leading to the production of ketone bodies – acetoacetate, beta‑hydroxybutyrate, and acetone – which accumulate in the blood, causing metabolic acidosis.

The condition does not develop suddenly; it often evolves over hours to days as hyperglycemia worsens and ketone levels rise. Early recognition by pharmacists can interrupt this progression before patients require intensive care. Understanding the precise pathophysiology helps pharmacists appreciate why symptoms such as fruity‑smelling breath (from acetone), Kussmaul respirations (a compensatory hyperventilation), and abdominal pain occur.

Recognizing the Classic Symptom Triad

The classic presentation of DKA includes polyuria, polydipsia, and weight loss, but these are often overshadowed by more alarming signs. Pharmacists should be especially attuned to the following symptoms during medication reviews:

  • Hyperglycemia – Typically blood glucose >250 mg/dL, though euglycemic DKA (glucose <200 mg/dL) can occur in patients using SGLT2 inhibitors.
  • Ketosis – Elevated blood or urine ketones (>3 mmol/L or high on urine dipstick).
  • Metabolic acidosis – Low serum bicarbonate (<18 mEq/L) and elevated anion gap.
  • Fruity‑smelling breath – A characteristic acetone odor that patients or family members may report.
  • Kussmaul respirations – Deep, rapid breathing as the body attempts to blow off carbon dioxide to compensate for acidosis.
  • Nausea, vomiting, and abdominal pain – Often mistaken for gastroenteritis; can be severe enough to mimic an acute abdomen.
  • Altered mental status – Ranging from lethargy to confusion or coma as acidosis and dehydration worsen.

Pharmacists should note that symptoms may be less pronounced in patients with chronic hyperglycemia, those on certain medications, or elderly individuals. Therefore, a standardized symptom screen during medication reviews is essential.

Differentiating DKA from Hyperosmolar Hyperglycemic State (HHS)

While both DKA and HHS are hyperglycemic emergencies, they differ in presentation. HHS typically features extremely high blood glucose (>600 mg/dL), minimal ketosis, and profound dehydration without significant acidosis. DKA involves acidosis and ketosis even at lower glucose levels. Pharmacists who encounter patients with glucose readings above 300 mg/dL, especially if accompanied by gastrointestinal symptoms or rapid breathing, should suspect DKA rather than simple hyperglycemia.

Risk Factors That Pharmacists Can Identify

Certain clinical scenarios increase the likelihood of DKA. During medication reviews, pharmacists should assess for these risk factors:

  • Non‑adherence to insulin therapy – Missed doses, improper storage, or patient refusal to take insulin.
  • Incorrect insulin administration – Using expired insulin, wrong injection technique, or malfunctioning insulin pumps.
  • Concomitant illnesses – Infection (especially pneumonia, urinary tract infection, gastroenteritis), myocardial infarction, or stroke.
  • Certain medications – Corticosteroids, thiazide diuretics, atypical antipsychotics, and SGLT2 inhibitors (euglycemic DKA).
  • Substance use – Alcohol, cocaine, or cannabis misuse can precipitate DKA.
  • Pregnancy – Physiological changes can unmask DKA at lower glucose levels.

By identifying these factors during a medication review, pharmacists can initiate preventive education or recommend early medical evaluation.

The Pharmacist’s Unique Position in Diabetes Care

Pharmacists are among the most accessible healthcare professionals. Patients with diabetes often visit pharmacies monthly to refill insulin or oral medications, providing numerous opportunities to detect early DKA warnings. Unlike physicians or nurses, pharmacists have dedicated time to review medication regimens, assess adherence, and discuss patients’ daily lived experiences with diabetes. This consistent, longitudinal contact makes the medication review a perfect setting for DKA screening.

How Medication Reviews Enable DKA Detection

A comprehensive medication review goes beyond checking for drug interactions. It is a structured conversation about the patient’s therapy, lifestyle, and self‑monitoring practices. Pharmacists can systematically evaluate:

  • Glucose monitoring data – Review blood glucose logs and patterns; look for unexplained highs or persistent ketones.
  • Insulin titration history – Determine if adjustments have been made appropriately or if the patient is frequently skipping doses.
  • Use of sick‑day protocols – Ask about management during illness, which is a common DKA trigger.
  • Patient symptoms – Directly inquire about recent nausea, vomiting, abdominal pain, or breath changes.
  • Medication triggers – Identify prescriptions that may increase DKA risk, such as SGLT2 inhibitors in patients with low carbohydrate intake or recent surgery.

By embedding DKA awareness into every diabetes‑related medication review, pharmacists transform a routine encounter into a potentially life‑saving intervention.

Subtle Signs That Pharmacists Should Not Overlook

Patients often do not spontaneously mention symptoms of DKA, especially if they attribute them to a stomach virus or stress. Pharmacists must ask specific, non‑judgmental questions. Warning signs that should raise suspicion include:

  • Reports of “feeling terrible” or extreme fatigue that is out of proportion to usual glycemic control.
  • Fruity or nail‑polish‑like breath odor noticed by the patient or family.
  • Unexplained rapid or deep breathing, even at rest.
  • Multiple episodes of vomiting or inability to keep down fluids and insulin.
  • Recent weight loss despite normal food intake.
  • Confusion or difficulty concentrating, especially in elderly patients.

Pharmacists should also be vigilant for euglycemic DKA, a variant where blood glucose is only mildly elevated (150–200 mg/dL) but ketones are markedly high. This is increasingly seen with SGLT2 inhibitor use, and patients may not associate their symptoms with diabetes. If a patient on an SGLT2 inhibitor reports nausea, vomiting, or malaise, checking ketones is imperative.

Practical Steps for Pharmacists During Medication Reviews

Implementing DKA screening into routine workflow requires a systematic approach. Below are actionable steps that pharmacists can integrate into their medication review process, whether in community, hospital, or ambulatory care settings.

Structured Interview Questions

Use a brief, patient‑friendly script to uncover DKA symptoms. For example:

  • “In the past few days, have you had any stomach upset, vomiting, or pain?”
  • “Have you noticed any changes in your breathing, like feeling winded or breathing fast?”
  • “Has anyone mentioned that your breath smells different, like fruit or nail polish?”
  • “When was the last time you tested your blood glucose? What was the reading? Have you tested for ketones?”
  • “Have you missed any doses of your insulin or changed how you take it?”
  • “Are you currently using any diabetes medications like dapagliflozin, empagliflozin, or canagliflozin?”

These questions should be integrated naturally into the conversation rather than recited like a checklist. A trusting pharmacist‑patient rapport encourages honest disclosure.

Reviewing Glucose and Ketone Data

Ask patients to bring their glucose meter or logbook to each visit. Look for patterns such as:

  • Persistent fasting hyperglycemia >250 mg/dL over 24–48 hours.
  • Rising glucose trend despite increased insulin doses.
  • Blood glucose readings above 300 mg/dL accompanied by symptoms.

If the patient uses a continuous glucose monitor (CGM), examine the trends for any sensor glucose values persistently above 250 mg/dL or rapid upward slopes. For patients with glucometers that test blood ketones, ask for those readings. A beta‑hydroxybutyrate level ≥ 3 mmol/L is consistent with DKA and warrants immediate medical referral.

When ketone test strips are available, encourage patients to test urine or blood ketones whenever their glucose exceeds 250 mg/dL or they feel unwell. Pharmacists can demonstrate proper technique and interpret results.

Educating Patients on Sick‑Day Rules

One of the most effective ways pharmacists can prevent DKA is through proactive education about managing illness. The so‑called “sick‑day rules” are critical for patients with type 1 diabetes and those using SGLT2 inhibitors:

  • Never skip insulin – Even if unable to eat, patients should still take their basal insulin. Stress the importance of continuing insulin during illness, as the body’s demand increases.
  • Monitor glucose and ketones frequently – Check every 2–4 hours during illness, and test for ketones if glucose is high or if nausea/vomiting occurs.
  • Stay hydrated – Drink sugar‑free or low‑sugar fluids (water, broth) in small amounts frequently.
  • Seek medical help early – If vomiting persists, ketones are moderate to large, or symptoms rapidly worsen, the patient should go to the emergency department.
  • Temporary use of rapid‑acting insulin – Educate about correction doses; some patients need additional short‑acting insulin every 2–4 hours when ill, but only under professional guidance.

Pharmacists can provide written sick‑day action plans or laminated cards that patients keep with their medications. This proactive education empowers patients to recognize early DKA signs and respond appropriately.

Collaborative Care and Referral Pathways

While pharmacists can identify DKA symptoms, management is a multidisciplinary effort. Clear referral pathways ensure that patients receive timely treatment, which may include intravenous fluids, insulin infusion, and electrolyte replacement.

When to Refer to Emergency Services

Pharmacists must know the red flags that indicate immediate hospital referral. These include:

  • Positive ketones (blood β‑hydroxybutyrate ≥ 3 mmol/L or large urine ketones) accompanied by vomiting or inability to keep down fluids.
  • Altered mental status – confusion, lethargy, or disorientation.
  • Kussmaul breathing or respiratory distress.
  • Signs of hypovolemic shock (tachycardia, hypotension, dry mucous membranes, poor skin turgor).
  • Persistent hyperglycemia >350 mg/dL despite following sick‑day rules.

In these situations, the pharmacist should advise the patient to go to the nearest emergency department immediately, or call emergency medical services. The pharmacist should also provide a brief clinical summary (medication list, glucose/ketone readings, symptoms) to the receiving physician if possible.

Coordinating with Primary Care and Endocrinology

For patients who present with milder hyperglycemia or early ketosis without severe acidosis, the pharmacist can contact the patient’s primary care provider or endocrinologist to discuss an outpatient management plan. This might involve:

  • Adjustment of insulin doses (e.g., increasing basal or bolus insulin).
  • Ordering laboratory tests (serum ketones, chemistry panel).
  • Prescribing antiemetics or oral fluids if appropriate.
  • Arranging a same‑day clinic visit.

Pharmacists should maintain a list of local endocrinologists, diabetes educators, and hospital diabetes teams to facilitate warm handoffs. Documenting the findings in the patient’s record and providing follow‑up instructions reinforces the continuity of care.

Using Technology to Enhance Detection

Modern pharmacy systems can help flag high‑risk patients. For example, electronic medication records can be set to alert pharmacists when a patient has not filled a basal insulin prescription for a significant interval, or when a new SGLT2 inhibitor is dispensed. These alerts can prompt a targeted medication review focused on DKA risk. Similarly, remote monitoring platforms allow pharmacists to review CGM data or blood glucose downloads for early detection of deteriorating control.

External resources such as the American Diabetes Association’s DKA page and Joslin Diabetes Center’s DKA information provide evidence‑based guidelines that pharmacists can use to educate themselves and their patients. Additionally, the NIH StatPearls article on Diabetic Ketoacidosis offers a comprehensive clinical overview that supports pharmacist decision‑making. For pharmacists working in hospitals, the ASHP guidelines on management of DKA outline the pharmacist’s role in inpatient settings.

Case Example: Detecting DKA in a Community Pharmacy

A 30‑year‑old woman with type 1 diabetes presents to refill her insulin prescription. Inquired about her glucose control, she mentions she has been feeling “really tired” and has had nausea for two days, which she attributes to a “stomach bug.” The pharmacist notes she uses a CGM, and her glucose readings for the past 24 hours are consistently above 280 mg/dL. When asked about breath changes, she recalls her husband said she smelled like “rubbing alcohol.” The pharmacist tests her urine ketones – they are “large.” Recognizing the classic DKA picture, the pharmacist advises immediate emergency evaluation. The patient goes to the ER, where she is diagnosed with mild DKA and treated with IV fluids and insulin. Her DKA resolves after 24 hours, and she later learns that a low‑grade infection had triggered the episode. The pharmacist’s proactive questioning and point‑of‑care testing prevented her from progressing to severe acidosis.

Conclusion

Pharmacists occupy a pivotal frontline role in identifying the early symptoms of diabetic ketoacidosis during medication reviews. By understanding the subtle presentations, asking targeted questions, reviewing monitoring data, and educating patients about sick‑day management, pharmacists can detect DKA before it becomes a life‑threatening crisis. This requires ongoing education, clinical vigilance, and strong collaboration with the broader diabetes care team. Embedding DKA screening into routine pharmacy practice not only saves lives but also reinforces the pharmacist’s role as an essential partner in diabetes care. Every medication review is an opportunity to prevent a preventable emergency – and pharmacists are uniquely positioned to seize it.